Ph 2 Trial of Vitamin C & G-FLIP (Low Doses Gemcitabine, 5FU, Leucovorin, Irinotecan, Oxaliplatin) for Pancreatic Cancer
Status:
Completed
Trial end date:
2020-01-01
Target enrollment:
Participant gender:
Summary
Pancreatic cancer, especially at advanced metastatic stage, is a devastating disease. It is
the fourth leading cause of cancer death. Its prognosis is grim - 5-year survival rate being
6%. The current therapies for advanced metastatic pancreatic cancer are very toxic and with
limited efficacy. A safer and more effective therapy for this devastating disease is greatly
needed.
G-FLIP regimen is a combination of low doses (doses lower than those approved by the FDA and
used in the clinic) of several anti-cancer drugs, Gemcitabine, Fluorouracil, Leucovorin,
Irinotecan and Oxaliplatin. The efficacy of G-FLIP against cancers (especially pancreatic
cancer) is based on laboratory and clinical results, which indicates the synergistic efficacy
of these anti-cancer drugs against cancer cells and overcoming tumor drug resistance that
cancer cells frequently develop. Also, because of their low doses, this regimen is less toxic
than when these drugs are used alone.
Meanwhile, intravenous infusion of high doses (doses significantly higher than the daily
nutritional requirements) of Vitamin C (ascorbic acid) has been observed to have anti-cancer
activities. This is especially true when Vitamin C is used in combination with other
anti-cancer drugs.